Zhejiang Starry Pharmaceutical Co., Ltd. (603520.SH) announced its plan to acquire a 20.00% equity stake in Jiangsu Ruishi Pharmaceutical Co., Ltd. from Ms. Li Yongping for 10 million yuan. Ruishi Pharma has established deep collaborations with renowned CDMO companies and leading innovative pharmaceutical firms both domestically and internationally. Its product portfolio includes small molecule compounds, amino acids and their derivatives, among other core raw materials, providing stable and reliable high-quality material support for clients from early drug development stages through regulatory submission, thereby accelerating the drug development process. The transaction is expected to enhance the company's CMO production capacity and facilitate the expansion of its downstream customer base.